erythema Clinical Trials

271 recruitingLast updated: July 25, 2026

There are 271 actively recruiting erythema clinical trials across 76 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Beijing, Beijing Municipality, China, New York, New York, United States, Beijing, China. Updated daily from ClinicalTrials.gov.


erythema Trials at a Glance

271 actively recruiting trials for erythema are listed on ClinicalTrialsFinder across 6 cities in 76 countries. The largest study group is Phase 1 with 93 trials, with the heaviest enrollment activity in Beijing, New York, and Beijing. Lead sponsors running erythema studies include AstraZeneca, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and China Immunotech (Beijing) Biotechnology Co., Ltd..

Treatments under study

About erythema Clinical Trials

Looking for clinical trials for erythema? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new erythema trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about erythema clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 271 trials

Recruiting

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

FibromyalgiaSystemic Lupus ErythematosusJuvenile Idiopathic Arthritis
Children's National Research Institute90 enrolled1 locationNCT04833465
Recruiting
Phase 1

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled14 locationsNCT07085104
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled233 locationsNCT06617325
Recruiting
Phase 2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled57 locationsNCT06570798
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled37 locationsNCT06916806
Recruiting

Study of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2,000 enrolled1 locationNCT00001372
Recruiting
Phase 3

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
AstraZeneca245 enrolled103 locationsNCT07430306
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled13 locationsNCT07332481
Recruiting
Phase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled138 locationsNCT07409181
Recruiting
Phase 3

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Lupus Erythematosus, SystemicNephritis, Lupus
Viatris Innovation GmbH300 enrolled14 locationsNCT07201129
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Lupus Erythematosus, Systemic
AstraZeneca218 enrolled22 locationsNCT07330245
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled65 locationsNCT07175285
Recruiting
Phase 4

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Systemic Lupus Erythematosus
AstraZeneca16 enrolled1 locationNCT06594068
Recruiting
Phase 1Phase 2

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
National Heart, Lung, and Blood Institute (NHLBI)78 enrolled1 locationNCT06032923
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Not Applicable

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

Rheumatoid ArthritisPsoriatic ArthritisSystemic Lupus Erythematosus+6 more
Terry L. Wahls400 enrolled1 locationNCT07180537
Recruiting
Phase 4

Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

Lupus Nephritis (LN)Childhood-onset Systemic Lupus Erythematosus
Peking Union Medical College Hospital198 enrolled8 locationsNCT07719140
Recruiting

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

Systemic Lupus Erythematosus (SLE)
AstraZeneca200 enrolled32 locationsNCT06314282
Recruiting
Phase 3

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Systemic Lupus Erythematosus
AstraZeneca100 enrolled99 locationsNCT05835310